A routine Sunday evening Lufthansa flight from Tel Aviv to Frankfurt turned into a life-threatening emergency when a flight attendant suffered a severe allergic reaction after unknowingly consuming sesame. Approximately two-thirds of the way through Flight LH687, the crew member, who had a severe sesame allergy, began feeling ill after eating just two bites of food containing the ingredient. He initially took antihistamines and steroids, neither of which is an adequate substitute for epinephrine in treating anaphylaxis. His condition rapidly deteriorated, and he lost consciousness, prompting an overhead announcement requesting assistance from medical professionals aboard the aircraft.
Among the passengers who responded was Dr Uriel Trachtenberg, director of the Intensive Care Department at Galilee Medical Center in Nahariya, Israel. When he reached the rear of the plane, he found the flight attendant lying on the floor, barely conscious, with swollen lips, heavy sweating, and confusion. Another crew member had attempted to administer an EpiPen, an automatic epinephrine injector used to treat severe allergic reactions. However, Trachtenberg discovered a potentially fatal mistake: “The other flight attendant told me he had injected him and showed me the device. I asked him to demonstrate what he had done, and he showed me how he had activated it in the air. I realized that the patient had not actually received the medication.”
With the flight attendant’s condition worsening, Trachtenberg opened the aircraft’s emergency medical kit, prepared a syringe containing epinephrine, and administered the medication. The process took approximately five minutes, after which the crew member initially stabilized. But the danger was far from over. Although epinephrine is the first-line treatment for anaphylaxis, symptoms can persist or return after initial improvement, making urgent medical evaluation essential. Trachtenberg contacted the cockpit to request an emergency landing, explaining, “I told the pilot that I was an intensive care physician and that this was a life-threatening situation.” Shortly afterward, the flight attendant again lost consciousness, experienced tremors, and suffered a significant drop in blood pressure. The pilots diverted to Belgrade, Serbia, where an ambulance transported him to a hospital.
Lufthansa subsequently expressed regret for the disruption, stating that “the safety of our passengers and crews is always the top priority of the Lufthansa Group.” Yet the incident raises troubling questions about aviation medical preparedness. Had Dr Trachtenberg not been aboard to recognize the failed EpiPen administration and prepare an injection, the outcome could have been fatal. Depending on the chance presence of an intensive care specialist is hardly a reliable emergency response strategy at 35,000 feet. Flight attendants are often the first responders during in-flight medical emergencies, yet this incident demonstrates how an error in administering an auto-injector can have potentially devastating consequences. While the circumstances do not establish whether inadequate training contributed to the mistake, they underscore the importance of practical, repeated instruction in recognizing and treating anaphylaxis.
Although this Lufthansa flight was not governed by US aviation regulations, the incident illustrates concerns raised by American allergy specialists about the adequacy of emergency medical supplies aboard commercial aircraft. In a commentary published in The Journal of Allergy and Clinical Immunology: In Practice and previously reported by SnackSafely, medical experts warned against a proposed Federal Aviation Administration (FAA) rule change. Under existing U.S. regulations, airline emergency medical kits must contain epinephrine, but the FAA’s proposed performance-based approach would eliminate the explicit medication requirement. Instead, airlines would be responsible for selecting supplies sufficient to treat nine categories of life-threatening emergencies, including anaphylaxis. Although the proposal identifies epinephrine as a possible treatment, it would no longer specifically mandate that airlines carry it.
The proposed change is particularly concerning because epinephrine is the first-line medication for anaphylaxis, and delays in administering it can have fatal consequences. Current US regulations allow airlines to satisfy their epinephrine requirement with single-dose ampules that must be drawn into a syringe before administration—a procedure requiring medical knowledge and potentially difficult to perform in a cramped, turbulent cabin. The Lufthansa incident illustrates both the importance of having epinephrine available and the challenges of administering it correctly, even when a ready-to-use device is present. Passengers also cannot always rely on their personal auto-injectors, which may be inaccessible in checked luggage, expired, or insufficient if a severe reaction requires additional doses. Replacing explicit medication requirements with broad standards risks introducing additional uncertainty into emergencies where every minute matters.
To protect passengers and crew, aviation authorities should establish clear, enforceable requirements rather than leaving essential anaphylaxis preparedness entirely to airline discretion. Emergency medical kits and accessible cabin first-aid supplies should be required to include ready-to-use epinephrine, such as auto-injectors or nasal sprays, in age- and weight-appropriate formulations for adults and children. Just as importantly, flight personnel should receive regular, hands-on training to recognize anaphylaxis and correctly administer these treatments without hesitation. The lesson from Flight LH687 is unmistakable: having life-saving medication aboard an aircraft is not enough if it cannot be administered promptly and correctly. Surviving an allergic emergency in the air should never depend on whether a qualified physician happens to be sitting nearby.
Remember that epinephrine is the only drug that can halt and reverse the progression of life-threatening anaphylaxis, but it must be administered quickly after symptoms begin to achieve the best outcome. Always carry two doses everywhere, every time, and show friends, family, and co-workers how to use your device in case you are unable to.
